Irrelevance of Explicit Cost–effectiveness Thresholds When Coverage Decisions Can Be Reversed

Expert Review of Pharmacoeconomics and Outcomes Research - United Kingdom
doi 10.1586/erp.13.8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited


Related search